|
US2003022260A1
|
|
Transcription factor - E2F-5
|
|
WO0226696A1
|
|
Carbamic acid compounds comprising an amide linkage as hdac inhibitors
|
|
AU5498001A
|
|
Assay for cell cycle modulators based on the modulation of cyclin d1 degradationin response to ionising radiation
|
|
US6387649B1
|
|
Assay for a regulator of cell cycle progression
|
|
GB0023982D0
|
|
Therapeutic Compounds
|
|
GB0023986D0
|
|
Therapeutic compounds
|
|
GB0023983D0
|
|
Therapeutic compounds
|
|
GB0023984D0
|
|
Therapeutic compounds
|
|
GB0023985D0
|
|
Therapeutic compounds
|
|
GB0013652D0
|
|
Therapeutic compounds
|
|
GB0013648D0
|
|
Therapeutic compounds
|
|
GB0013649D0
|
|
Therapeutic compounds
|
|
GB0013650D0
|
|
Therapeutic compounds
|
|
GB0013655D0
|
|
Therapeutic compounds
|
|
GB9908171D0
|
|
Gene and use thereof
|
|
US6303335B1
|
|
Transcription factor E2F-4
|
|
AU2533499A
|
|
Interaction between cyclin d1 and steroid receptor co-activators and uses thereof in assays
|
|
GB9901710D0
|
|
Peptide inhibitors
|
|
US6159691A
|
|
Assay for a putative regulator of cell cycle progression
|
|
GB9818243D0
|
|
Improvements relating to assays
|
